2.33
price down icon4.12%   -0.10
pre-market  プレマーケット:  2.38   0.05   +2.15%
loading
前日終値:
$2.43
開ける:
$2.43
24時間の取引高:
1.18M
Relative Volume:
0.45
時価総額:
$279.18M
収益:
$6.65M
当期純損益:
$-136.32M
株価収益率:
-2.0301
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
-7.54%
1か月 パフォーマンス:
-4.51%
6か月 パフォーマンス:
+106.19%
1年 パフォーマンス:
+130.69%
1日の値動き範囲:
Value
$2.27
$2.43
1週間の範囲:
Value
$2.27
$2.63
52週間の値動き範囲:
Value
$0.95
$3.23

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1068)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
161
Name
Twitter
@fatethx
Name
次回の収益日
2026-11-12
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

Compare FATE vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FATE icon
FATE
Fate Therapeutics Inc
2.33 279.18M 6.65M -136.32M -112.04M -1.1477
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
522.38 132.40B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
796.02 81.95B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
194.82 77.78B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
962.22 60.20B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
199.86 42.84B 742.00K -1.37B -1.07B -7.0731

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-05-19 再開されました Jefferies Buy
2025-10-31 アップグレード H.C. Wainwright Neutral → Buy
2025-10-27 アップグレード Wedbush Neutral → Outperform
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
07:14 AM

Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com - Investing.com Canada

07:14 AM
pulisher
07:11 AM

Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - quiverquant.com

07:11 AM
pulisher
Sep 23, 2026

Fate Therapeutics Inc (F6T.MU) stock price, news, quote and history - Yahoo Finance UK

Sep 23, 2026
pulisher
Sep 18, 2026

Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine

Sep 18, 2026
pulisher
Sep 16, 2026

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewswire

Sep 16, 2026
pulisher
Sep 14, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat

Sep 14, 2026
pulisher
Sep 09, 2026

Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 09, 2026

Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

FATE: Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative

Sep 09, 2026
pulisher
Sep 09, 2026

FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill

Sep 09, 2026
pulisher
Sep 09, 2026

Fate Therapeutics Announces Encore Clinical Data - GlobeNewswire

Sep 09, 2026
pulisher
Sep 08, 2026

Fate Therapeutics Market Sentiment - Benzinga España

Sep 08, 2026
pulisher
Sep 06, 2026

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits

Sep 06, 2026
pulisher
Sep 06, 2026

Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España

Sep 06, 2026
pulisher
Sep 04, 2026

Fate Therapeutics stock holds steady as investors watch cash runway and pipeline - ad-hoc-news.de

Sep 04, 2026
pulisher
Sep 03, 2026

FATE Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusPost-Earnings Drift - vinanet.vn

Sep 03, 2026
pulisher
Sep 03, 2026

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference - Yahoo Finance

Sep 03, 2026
pulisher
Sep 03, 2026

BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE - MarketBeat

Sep 03, 2026
pulisher
Sep 03, 2026

Fate Therapeutics stock stabilizes after autoimmune CAR-T safety shock - ad-hoc-news.de

Sep 03, 2026
pulisher
Sep 02, 2026

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE) - Seeking Alpha

Sep 02, 2026
pulisher
Aug 30, 2026

574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat

Aug 30, 2026
pulisher
Aug 27, 2026

487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC - marketbeat.com

Aug 27, 2026
pulisher
Aug 20, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Aug 20, 2026
pulisher
Aug 17, 2026

Fate Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 17, 2026
pulisher
Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026
pulisher
Aug 16, 2026

Fate Therapeutics (FATE) Gains 1.98% to $2.57 as Stock Holds Above Key SupportStock News - dars.gov.et

Aug 16, 2026
pulisher
Aug 16, 2026

Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE - MarketBeat

Aug 16, 2026
pulisher
Aug 15, 2026

Fate Therapeutics (FATE) Rises 1.98% to $2.57 as it Approaches Key ResistanceAdvance Decline Line - vinanet.vn

Aug 15, 2026
pulisher
Aug 15, 2026

Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Australia

Aug 14, 2026
pulisher
Aug 14, 2026

Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $8 - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis - BioPharm International

Aug 14, 2026
pulisher
Aug 14, 2026

Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat

Aug 14, 2026
pulisher
Aug 14, 2026

Fate Therapeutics doses first patient in FT819 lupus trial - Investing.com

Aug 14, 2026
pulisher
Aug 14, 2026

Fate Therapeutics doses first patient in FT819 lupus trial By Investing.com - Investing.com Nigeria

Aug 14, 2026
pulisher
Aug 14, 2026

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis - Quiver Quantitative

Aug 14, 2026
pulisher
Aug 14, 2026

Fate Therapeutics' First FT819 Patient Went Home Same Day - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

FATE THERAPEUTICSPATIENTS TO RECEIVE SINGLE 900 MLN-CELL DOSE OF FT819; PRIMARY ENDPOINT AT WEEK 26 - webull.com

Aug 14, 2026
pulisher
Aug 13, 2026

FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5 - Bitget

Aug 13, 2026
pulisher
Aug 13, 2026

Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo! Finance Canada

Aug 13, 2026
pulisher
Aug 13, 2026

Fate Therapeutics Reports Q2 2026 10-Q Filing Highlighting iPSC Pipeline and Key Risks - Kalkine Media

Aug 13, 2026
pulisher
Aug 13, 2026

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aug 13, 2026
pulisher
Aug 13, 2026

Form 8K Fate Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia

Aug 13, 2026
pulisher
Aug 13, 2026

Fate Therapeutics: Q2 Earnings Snapshot - marketscreener.com

Aug 13, 2026

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$58.29
price up icon 1.11%
$36.13
price down icon 1.87%
$121.55
price up icon 2.71%
$249.59
price up icon 1.25%
ONC ONC
$359.97
price down icon 1.38%
$199.86
price up icon 4.78%
大文字化:     |  ボリューム (24 時間):